A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG

Inclusion Criteria: * • Subjects must voluntarily sign and date an informed consent, ap-proved by an independent ethics committee (IEC)/institutional review board (IRB) * Documented diagnosis of CLL at time point of inclusion in a first-line study of the GCLLSG (development of RT is not an exclusion criterion) * First-line treatment was administered within one of these first-line studies of the GCLLSG (CLL13, CLL14, or CLL17). * Subsequent therapy lines were either documented during the participa-tion in a first-line study of the GCLLSG or patient consented to have the subsequent therapy lines documented within this observational trial. * Subjects are willing and able to comply with procedures required in this protocol. Exclusion Criteria: * • Patients without participation in one of the first-line studies of the GCLLSG (CLL13, CLL14, CLL17) * Subjects with legal incapacity * Subjects who are institutionalized by regulatory or court order * Subjects who are in dependence to the sponsor or the investigator